Blend Therapeutics

Latest Headlines

Latest Headlines

Langer-backed biotech reboots with $38M, new name and new cancer drug tech

Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program and focusing on a new top drug and platform tech with a $38 million C round. And it's taking a new name to help underscore the shift in focus.

Drew Fromkin takes the helm at Langer's Blend Therapeutics

Blend Therapeutics, which was founded by Omid Farokhzad and MIT's Robert Langer, has named Drew Fromkin as its new CEO.

Blend banks $21M for its nano-assisted cancer drugs

Blend Therapeutics, a biotech with ties to MIT serial entrepreneur Robert Langer, has hauled in $21 million in new financing to flesh out a novel approach to cancer treatment.

Blend Therapeutics secures Mark Iwicki's talents

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...

Langer biotech adds $16M in venture cash to back next-gen cancer drugs

The startup biotech Blend Therapeutics rang in 2012 with seed cash and will now close out the year with a fresh injection of $16 million in B-round bucks budgeted to take this startup--one of the latest from the prolific scientist Robert Langer--right to the threshold of clinical development.

Exclusive: MIT's Langer, Farokhzad launch combination-med biotech

Serial biotech entrepreneurs Robert Langer and Omid Farokhzad are joining up with MIT's Dr. Stephen Lippard to launch a new drug developer--Blend Therapeutics--which will concentrate on the